Drug Trial Radar · NCT04718844
A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Apr 14, 2021
Primary completion
May 23, 2023
Study completion May 23, 2023
Sponsor
- Lead sponsor
- Silence Therapeutics plcIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome (MDS) after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 cohorts of 56 patients with MDS will be enrolled. Each subject will receive single or multiple doses of SLN124 or placebo given by subcutaneous (s.c) injection.
Conditions
- Non-transfusion-dependent Thalassemia
- Low Risk Myelodysplastic Syndrome
- Very-Low Risk Myelodysplastic Syndrome
Interventions
SLN124Drug
SLN124 for subcutaneous (s.c.) injection
PlaceboDrug
Sodium chloride for s.c. injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: Day 84
- Incidence of treatment-emergent adverse eventsTime frame: Day 140
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Universitaetsklinikum Duesseldorf
Düsseldorf, Germany
Universitat Leipzig
Leipzig, Germany
Rambam Health Care Campus
Haifa, Israel
Sheba Medical Center
Ramat Gan, Israel
Bar-Ilan University - Faculty of Medicine
Safed, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
AUSL della Romagna - Ospedale di Ravenna
Ravenna, Italy
Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
Reggio Emilia, Italy
Jordan University Hospital
Amman, Jordan
King Hussein Cancer Center
Amman, Jordan
Irbid Speciality Hospital
Irbid, Jordan
Sarawak General Hospital
Kampung Sarawak, Malaysia
Hospital Ampang
Kampung Selangor, Malaysia
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Mahidol University - Faculty of Medicine - Ramathibodi Hospital
Bangkok, Thailand
Mahidol University - Siriraj Hospital
Bangkok, Thailand
Faculty of Medicine, Chiang Mai University
Chiang Mai, Thailand
University Hospital of Wales
Cardiff, United Kingdom
The Leeds Teaching Hospitals NHS Trust - Saint James's University Hospital
Leeds, United Kingdom
Hammersmith Medicines Research Ltd (HMR)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.